Yahoo
NasdaqGM - Delayed Quote USD

ABIVAX Société Anonyme (ABVX)

115.99 +4.56 (+4.09%)
At close: April 22 at 4:00:01 PM EDT
114.91 -1.08 (-0.93%)
Pre-Market: 8:28:45 AM EDT
Trade Abivax on Coinbase
Chart Range Bar
Loading chart for ABVX
  • Previous Close 111.43
  • Open 113.40
  • Bid 115.64 x 200
  • Ask 116.23 x 300
  • Day's Range 111.82 - 115.99
  • 52 Week Range 5.59 - 148.83
  • Volume 655,005
  • Avg. Volume 934,300
  • Market Cap (intraday) 9.443B
  • Beta (5Y Monthly) -0.10
  • PE Ratio (TTM) --
  • EPS (TTM) -5.70
  • Earnings Date Mar 23, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 155.20

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

www.abivax.com

69

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: ABVX

Trailing total returns as of 4/23/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

ABVX
16.16%
CAC 40 (^FCHI)
0.67%

1-Year Return

ABVX
1,684.46%
CAC 40 (^FCHI)
9.65%

3-Year Return

ABVX
899.91%
CAC 40 (^FCHI)
8.28%

5-Year Return

ABVX
899.91%
CAC 40 (^FCHI)
31.10%

Earnings Trends: ABVX

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 470k
Earnings -81.96M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-150M
-100M
-50M
0

Analyst Insights: ABVX

View More

Analyst Price Targets

131.00
155.20 Average
115.99 Current
176.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/24/2026
Analyst Barclays
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 142 -> 148

Statistics: ABVX

View More

Valuation Measures

Annual
As of 4/22/2026
  • Market Cap

    9.23B

  • Enterprise Value

    8.61B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    17.15

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -38.95%

  • Return on Equity (ttm)

    -135.58%

  • Revenue (ttm)

    4.57M

  • Net Income Avi to Common (ttm)

    -336.1M

  • Diluted EPS (ttm)

    -5.70

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    530.38M

  • Total Debt/Equity (mrq)

    7.05%

  • Levered Free Cash Flow (ttm)

    -118.32M

Compare To: ABVX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: ABVX

Fair Value

115.99 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: